The completed PMS facility spans over 80,000-sq-ft with an additional 20,000-sq-ft reserved for future growth and expansion.

Researchers suggest targeting inflammation may offer a promising therapeutic strategy at the intersection of cancer and cardiovascular disease.

VantAI's AI platform will accelerate programmable protein interaction therapies across Halda's cancer and immunology indications.

Stem cells cryopreserved on the International Space Station for six months have successfully produced healthy mouse offspring ...

Researchers say minimizing prenatal and early life exposure to CPF and other pesticides is likely important for optimal ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

BioMADE’s investment in Iowa is expected to provide access to the technology infrastructure required to determine if a product is commercially viable.

Researchers say COMET’s architecture may also support other areas of nanotechnology where multi-component formulations are critical.

PepMLM generates binders to challenging therapeutic targets across cancer and neurological disease using protein sequence and ...

Dementia-like protein clumps found in pancreatic precancer mouse cells point to autophagy defects, offering cancer ...

Researchers plan to collaborate on preclinical trials to apply polymersomes to real-world vaccine or drug delivery challenges ...

Made Scientific's new facility opening marks the completion of a $12 million initial investment in facility upgrades and equipment.